You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve as well as links to the week’s most important news.
Earnings season for the MSOs kicked off this past week, with Curaleaf, Acreage Holdings and Ayr Wellness reporting. We had expected Curaleaf to provide annual guidance, and the company indicated on its conference call that it projects 2021 revenue will be between $1.2 and $1.3 billion, with an adjusted EBITDA margin of approximately 30%. Ayr Wellness provided guidance for 2022, suggesting it will deliver $725 million in revenue and $325 million in adjusted EBITDA. We are glad to see an increasing number of companies provide annual guidance.
While we weren’t expecting it, one thing that we hoped to see didn’t materialize: better disclosure regarding the operations. One of the biggest challenges for analysts trying to understand what’s driving revenue and margins is that MSOs don’t provide state-by-state detail typically. A rare exception has been Vireo Health, which not only breaks down their revenue by state but also then divides it by state into retail and wholesale. The company, however, doesn’t provide profitability by state. We note that Ayr Wellness provided enough information in its press release for investors to see exactly how much revenue was generated in each of their two states of operation during the quarter, and it also split it between wholesale and retail. We haven’t seen any other MSOs provide this level of detail, though we expect Jushi Holdings could do so given that the company provided guidance for 2021 that included ranges for each of their states of operation.
MSOs are essentially holding companies, with each of their subsidiaries working as separate units state-by-state due to the prohibition of interstate commerce. The dynamics in each state can differ greatly, with some markets allowing much higher profitability due to more limited licensing. We believe investors currently lack essential information when they are given just the top level revenue and profitability without the underlying detail, and we hope that companies will begin providing more granular information regarding their operations.
To be clear, there is no legal requirement for MSOs to provide this better disclosure. We applaud the effort by more companies to begin providing revenue by state, and we hope that others will do so as well and perhaps provide profitability by state too. We have spoken to some of the management teams, and they certainly understand our point. It seems that the issue is that nobody wants to go first. The cannabis investor base is rapidly evolving, and we are hopeful that the increasing number of institutional investors will help persuade the MSOs to provide better disclosure regarding the sources of revenue and profits. We believe that providing this information will help investors better understand the companies and will ultimately boost their confidence.
For in-depth insights and analysis into the publicly-traded cannabis industry, there is no better source than Alan Brochstein’s 420 Investor premium service. Join the only due diligence platform trusted by cannabis investors for more than 7 years.
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:
- Ayr Wellness Q4 Revenue Increases 48% to $47.8 Million
- Cannabis SPAC Silver Spike Acquisition Corp II Raises $250 Million in NASDAQ IPO
- Curaleaf Q4 Revenue Increases 26% Sequentially to $230 million
- Exclusive: London-Listed Kanabo Is Bringing Vape Tech to Israeli and European Cannabis Markets
- Exclusive: Planet 13 Powers Through Pandemic as It Builds War Chest to Finance Expansion
- Tobacco Giant Takes 20% Stake in Organigram for C$221 Million
To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.
Get ahead of the crowd! If you are a cannabis investor and find value in our Sunday newsletters, subscribe to 420 Investor, Alan’s comprehensive stock due diligence platform since 2013. Gain immediate access to real-time and in-depth information and market intelligence about the publicly traded cannabis sector, including daily videos, weekly chats, model portfolios, a community forum and much more.
Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer a family of indices to track Canadian licensed producers as well as the American Cannabis Operator Index.
View the Public Cannabis Company Revenue & Income Tracker, which ranks the top revenue producing cannabis stocks that generate industry sales of more than US$12.5M per quarter.
Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.
Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.
Alan & Joel